Hims(US:HIMS) The Motley Fool·2026-02-09 22:30Core Viewpoint - Hims & Hers is facing significant challenges after withdrawing its weight-loss pill due to legal action and FDA scrutiny, leading to a sharp decline in stock price and market reevaluation by investors [1][5]. Company Performance - Hims & Hers Health's stock closed at $19.32, down 16.07%, with a market cap of $5.2 billion [2]. - The stock has dropped 26.89% over the past five days, primarily due to legal and regulatory pressures [5]. - Trading volume reached 143.5 million shares, significantly above the three-month average of 18.2 million shares [3]. Regulatory and Legal Issues - The company announced the withdrawal of its copycat version of the obesity drug Wegovy amid regulatory pressure [5]. - A lawsuit from Novo Nordisk seeks to ban Hims & Hers from selling compounded copies of its patented drugs [6]. - The FDA has indicated a crackdown on unauthorized use of GLP-1 active pharmaceutical ingredients, impacting Hims & Hers' operations [6]. Strategic Shift - Hims & Hers plans to pivot away from controversial compounded medicines and focus on other health conditions and AI health capabilities [6].